GDF3 is an endogenous antagonist of the ActE-ALK7/ACVR2 pathway in adipocytes
Nagasuryaprasad Kotikalapudi, Deepti Ramachandran, Evelyn Y Zhou, James Anthony Howard, Cadence J Vieira, Wei‐An Chen, SARAH HSU, Kyung Cheul Shin, Shirish Naz, Zhenghui Gordon Jiang, Josep Maria Mercader, Thomas B. Thompson, Stephen E Flaherty, Paul M. Titchenell, Henning Fritz Kramer, Alexander S. Banks
This study identifies GDF3 as an endogenous inhibitor of the ActE-ALK7 pathway in adipocytes, showing its role in metabolic diseases like MASLD/MASH and suggesting GDF3 inhibition as a therapeutic target.
bioRxiv · Sep 24, 2026 · PreprintPhysiology